Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
91 hedge funds and large institutions have $54.8M invested in Eagle Pharmaceuticals, Inc. in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 37 reducing their positions, and 29 closing their positions.
3.34% more ownership
Funds ownership: 77.15% → 80.49% (+3.3%)
5% more capital invested
Capital invested by funds: $52.4M → $54.8M (+$2.38M)
13% less funds holding
Funds holding: 104 → 91 (-13)
32% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 37
45% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 29
92% less call options, than puts
Call options by funds: $16K | Put options by funds: $202K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.91M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$6.51M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.12M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$760K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$624K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$4.06M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$3.9M |
| 3 |
Millennium Management
New York
|
-$1.45M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.29M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$718K |
EGRX Hedge Fund Activity: Q1 2024 in Review
91 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2024, worth a combined $54.8M — up 4.5% from $52.4M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of EGRX and 16 opened new positions — a net loss of 13 holders — while 37 trimmed existing stakes and 25 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $6.91M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $4.06M sold.
- 91 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2024, down from 104 in Q4 2023.
- Funds reported $54.8M of Eagle Pharmaceuticals, Inc. stock for Q1 2024, up 4.5% quarter-over-quarter.
- 16 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2024 and 29 closed out, a net change of -13 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2024 was Nantahala Capital Management, an estimated $6.91M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2024 was Janus Henderson Group, an estimated $4.06M sold.
Based on aggregated 13F filings for Q1 2024.